Assessment of efficacy, safety, and prognostic/predictive factors of nintedanib/docetaxel in advanced/recurrent non–small cell lung cancer post-immunotherapy and chemotherapy: A Galician Lung Cancer Group study
Nintedanib and docetaxel demonstrated meaningful efficacy and an acceptable safety profile in advanced NSCLC after immunotherapy and chemotherapy failure. LDH, PD-L1, and smoking status emerged as important prognostic factors, warranting further prospective studies.
Authors
- Lucía Santomé Couto
- Martín Lázaro Quintela
- Joaquín Mosquera (ORCID: https://orcid.org/0000-0002-4101-5490)
- Francisco Javier Afonso Afonso
- Cristina Azpitarte Raposeiras
- Natalia Fernández Núñez (ORCID: https://orcid.org/0000-0002-6503-395X)
- María Carmen Areses Manrique
- Jorge García (ORCID: https://orcid.org/0000-0001-7672-9867)
Institutions
- Universidade da Coruña (ES)
- University Hospital Complex Of Vigo (ES)
- Povisa Hospital (ES)
- Complexo Hospitalario Universitario A Coruña (ES)
- Hospital Universitario Lucus Augusti (ES)
- Instituto de Investigación Sanitaria de Santiago (ES)
- Complejo Hospitalario de Ourense (ES)
- Complejo Hospitalario Universitario de Ferrol (ES)
Publication Details
- Journal
- Cancer Treatment and Research Communications
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1016/j.ctarc.2025.100963
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00